GMAX Bio Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
74
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
GMAX Bio General Information
Description
Developer of therapeutic antibodies designed for cardiovascular diseases, metabolic disorders, and cancer. The company's technology utilizes an in-house antibody development platform, antibody humanization, and engineering, providing healthcare providers with monoclonal antibodies and fusion proteins for the treatment of diabetes, obesity, and heart failure.
Contact Information
Website
www.gmaxbiopharm.comCorporate Office
- 3rd Floor, Building 2
- Number 288 Qiuyi Road, Binjiang District
- Hangzhou, Zhejiang 310050
- China
Corporate Office
- 3rd Floor, Building 2
- Number 288 Qiuyi Road, Binjiang District
- Hangzhou, Zhejiang 310050
- China
GMAX Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 06-Jul-2026 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 26-Jun-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 05-Mar-2021 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | 18-Apr-2018 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 27-Nov-2017 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC | 12-Dec-2016 | $4.28M | $11.3M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 01-Dec-2014 | $7.01M | $7.01M | Completed | Pre-Clinical Trials |
GMAX Bio Comparisons
Industry
Financing
Details
GMAX Bio Competitors (28)
One of GMAX Bio’s 28 competitors is Mabworks Biotech, a Venture Capital-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mabworks Biotech | Venture Capital-Backed | Beijing, China | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Gracell | Formerly VC-backed | Shanghai, China | ||||
| CureGenetics | Venture Capital-Backed | Suzhou, China | ||||
| Adagene | Formerly VC-backed | Suzhou, China |
GMAX Bio Patents
GMAX Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026021575-A1 | Pharmaceutically stable solution formulation with gipr antibody fusion protein and use thereof | Pending | 26-Jul-2024 | ||
| AU-2023337288-A1 | Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof | Pending | 08-Sep-2022 | ||
| EP-4585617-A1 | Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof | Pending | 08-Sep-2022 | ||
| EP-4585617-A4 | Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof | Pending | 08-Sep-2022 | ||
| US-20260356962-A1 | Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof | Pending | 08-Sep-2022 | C07K16/2869 |
GMAX Bio Signals
GMAX Bio Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brill Capital | Family Office | Minority | ||
| China Merchants Group | Holding Company | Minority | ||
| Cowin Capital | Venture Capital | Minority | ||
| Dongguan Group | Corporation | Minority | ||
| Fellow Partners | Venture Capital | Minority |
GMAX Bio Investments (1)
GMAX Bio’s most recent deal was a Early Stage VC with Teligene. The deal was made on 01-Apr-2012.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Teligene | 01-Apr-2012 | Early Stage VC | Pharmaceuticals |
GMAX Bio FAQs
-
When was GMAX Bio founded?
GMAX Bio was founded in 2010.
-
Where is GMAX Bio headquartered?
GMAX Bio is headquartered in Hangzhou, China.
-
What is the size of GMAX Bio?
GMAX Bio has 74 total employees.
-
What industry is GMAX Bio in?
GMAX Bio’s primary industry is Drug Discovery.
-
Is GMAX Bio a private or public company?
GMAX Bio is a Private company.
-
What is GMAX Bio’s current revenue?
The current revenue for GMAX Bio is .
-
How much funding has GMAX Bio raised over time?
GMAX Bio has raised $94.3M.
-
Who are GMAX Bio’s investors?
Brill Capital, China Merchants Group, Cowin Capital, Dongguan Group, and Fellow Partners are 5 of 6 investors who have invested in GMAX Bio.
-
Who are GMAX Bio’s competitors?
Mabworks Biotech, CytomX Therapeutics, Gracell, CureGenetics, and Adagene are some of the 28 competitors of GMAX Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process